{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-033196","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2023-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.734867+00:00","generated_at":"2026-06-13T07:31:37.095125+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Larimar Therapeutics appoints Russell Clayton as CMO, 180K stock option inducement grant","bullets":["Russell 'Rusty' Clayton appointed Chief Medical Officer effective July 17, 2023, succeeding Nancy M. Ruiz (retiring).","Dr. Clayton previously served as Principal at Aeremedea, LLC and as advisor to Larimar for 5 years.","Inducement award of 180,000 stock options granted under Nasdaq Listing Rule 5635(c)(4), vesting over 4 years.","Dr. Clayton brings ~20 years of rare disease experience, including roles at Alcresta Therapeutics and Merck."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-033196","json":"https://secwatch.observer/filing/0000950170-23-033196.json","markdown":"https://secwatch.observer/filing/0000950170-23-033196.md","text":"https://secwatch.observer/filing/0000950170-23-033196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023033196/0000950170-23-033196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023033196/lrmr-20230717.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:31:37.095125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}